Healthcare stocks are mixed this afternoon with the NYSE Healthcare Sector Index rising about 0.3% while shares of healthcare companies in the S&P 500 are slipping less than 0.1% as a group.
In company news, BioMarin Pharmaceutical Inc. ( BMRN ) is up nearly 4% at $76.16 a share, revisiting its intra-day high in late afternoon trade after the early-stage drug-maker said its Vimizim drug candidate for the treatment of Morquio A will be reviewed by a U.S. Food and Drug Administration advisory committee on November 19.
The advisory panel reviews are the next-to-last stop for a prospective new drug before being cleared for U.S. sales. The full agency isn't required to follow the panel decision although it typically does.
In other sector news,
(+) KYTH, Blows past its former 52-week high to climb after saying its experimental injectable drug succeeded in reducing double chin in patients during late-stage studies.
(-) RTMI, FDA accepts Triferic as the trade name for the company's investigational drug to treat iron deficiency.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
